NSCLC Stage IV Clinical Trials

23 recruiting

NSCLC Stage IV Trials at a Glance

25 actively recruiting trials for nsclc stage iv are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 16 trials, with the heaviest enrollment activity in Shanghai, Rome, and Chongqing. Lead sponsors running nsclc stage iv studies include Fudan University, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Xinqiao Hospital of Chongqing.

Browse nsclc stage iv trials by phase

Treatments under study

About NSCLC Stage IV Clinical Trials

Looking for clinical trials for NSCLC Stage IV? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NSCLC Stage IV trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NSCLC Stage IV clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting
Phase 3

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

NSCLC Stage IV
ImmunityBio, Inc.507 enrolled19 locationsNCT06745908
Recruiting
Phase 2

A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy

NSCLC Stage IVEGFR Gene Mutation
Tianjin Medical University Cancer Institute and Hospital25 enrolled1 locationNCT07548060
Recruiting
Phase 2

Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NSCLC Stage IV
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer30 enrolled20 locationsNCT06552234
Recruiting
Phase 2

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

NSCLC Stage IV
European Organisation for Research and Treatment of Cancer - EORTC136 enrolled16 locationsNCT06219317
Recruiting
Phase 1Phase 2

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

NSCLC Stage IVNSCLC, Recurrent
University of Kansas Medical Center25 enrolled2 locationsNCT04467723
Recruiting
Phase 1Phase 2

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins12 enrolled1 locationNCT05950139
Recruiting
Phase 2

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

NSCLC Stage IV
Fudan University105 enrolled1 locationNCT04136535
Recruiting
Phase 2

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases

NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing427 enrolled1 locationNCT06947694
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC

NSCLC Stage IVMalignant Pleural Effusions
Wuhan YZY Biopharma Co., Ltd.96 enrolled1 locationNCT05543330
Recruiting
Phase 2

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

NSCLC Stage IV Without EGFR/ALK Mutation
Xinqiao Hospital of Chongqing366 enrolled1 locationNCT06953843
Recruiting
Not Applicable

Outpatient Pulmonary Rehabilitation in Non-small-cell Lung Cancer Receiving Immunotherapy

NSCLC Stage IV
Karl Landsteiner Institute for Lung Research and Pneumological Oncology70 enrolled1 locationNCT06436625
Recruiting

Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations

NSCLCNSCLC Stage IVNSCLC, Recurrent
Shanghai Chest Hospital500 enrolled2 locationsNCT05701787
Recruiting
Phase 2

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Brain Metastases, AdultNSCLC Stage IV
Maastricht University Medical Center25 enrolled3 locationsNCT06401824
Recruiting
Phase 2

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

NSCLC Stage IV
Fudan University59 enrolled1 locationNCT04767009
Recruiting

Lung Cancer Registry

Lung CancerNSCLC Stage IV
Arbeitsgemeinschaft medikamentoese Tumortherapie500 enrolled3 locationsNCT04654364
Recruiting
Phase 2

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

NSCLC Stage IVNSCLC Stage IIIB
Goethe University50 enrolled16 locationsNCT05281406
Recruiting

AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer

NSCLC Stage IV
IRCCS San Raffaele2,000 enrolled1 locationNCT06788366
Recruiting
Phase 2

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis

NSCLC Stage IV
Fudan University40 enrolled1 locationNCT06501378
Recruiting
Phase 2

Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis

Brain MetastasesNSCLC Stage IV
Fudan University54 enrolled1 locationNCT06501391